- Home
- CTXR vs ADAG Comparison
CTXR vs ADAG Comparison
Compare CTXR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTXR
- ADAG
- Stock Information
- Founded
- CTXR 2007
- ADAG 2011
- Country
- CTXR United States
- ADAG China
- Employees
- CTXR N/A
- ADAG N/A
- Industry
- CTXR Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- CTXR Health Care
- ADAG Health Care
- Exchange
- CTXR Nasdaq
- ADAG Nasdaq
- Market Cap
- CTXR 84.9M
- ADAG 95.6M
- IPO Year
- CTXR N/A
- ADAG 2021
- Fundamental
- Price
- CTXR $0.20
- ADAG $2.14
- Analyst Decision
- CTXR Strong Buy
- ADAG Strong Buy
- Analyst Count
- CTXR 2
- ADAG 1
- Target Price
- CTXR $5.00
- ADAG $5.00
- AVG Volume (30 Days)
- CTXR 2.0M
- ADAG 73.9K
- Earning Date
- CTXR 12-27-2024
- ADAG 07-25-2024
- Dividend Yield
- CTXR N/A
- ADAG N/A
- EPS Growth
- CTXR N/A
- ADAG N/A
- EPS
- CTXR N/A
- ADAG N/A
- Revenue
- CTXR N/A
- ADAG $815,746.00
- Revenue This Year
- CTXR N/A
- ADAG N/A
- Revenue Next Year
- CTXR N/A
- ADAG $2.70
- P/E Ratio
- CTXR N/A
- ADAG N/A
- Revenue Growth
- CTXR N/A
- ADAG N/A
- 52 Week Low
- CTXR $0.19
- ADAG $1.34
- 52 Week High
- CTXR $1.07
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- CTXR 29.06
- ADAG 37.47
- Support Level
- CTXR $0.31
- ADAG $2.20
- Resistance Level
- CTXR $0.51
- ADAG $3.14
- Average True Range (ATR)
- CTXR 0.06
- ADAG 0.30
- MACD
- CTXR -0.01
- ADAG -0.09
- Stochastic Oscillator
- CTXR 3.83
- ADAG 18.63
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.